Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;97(17):e0589.
doi: 10.1097/MD.0000000000010589.

Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins

Affiliations

Impact of von Willebrand factor on coronary plaque burden in coronary artery disease patients treated with statins

Yuta Kato et al. Medicine (Baltimore). 2018 Apr.

Abstract

High von Willebrand factor (VWF) levels have been reported to be associated with an increased risk of cardiovascular events. However, the relationship between VWF levels and coronary atherosclerosis in patients with coronary artery disease (CAD) who have already received stain treatment is still unclear. We examined the association between VWF levels and coronary plaque as assessed by intravascular ultrasound (IVUS) in CAD patients treated with statins. Ninety-one CAD patients who underwent percutaneous coronary intervention under IVUS guidance, and who were already receiving statin treatment based on Japanese guidelines, were included. An IVUS examination was performed for the culprit lesion, and plasma VWF antigen levels were measured using enzyme-linked immuno sorbent assay. In all of the patients, the low-density lipoprotein cholesterol levels just before the IVUS examination were low (86 ± 26 mg/dL). The VWF levels were positively correlated with the plaque burden expressed as percent atheroma volume (PAV) (r = 0.39, P = .001), while there was no significant association between VWF and plaque composition. Multivariate stepwise regression analysis showed that higher VWF levels were independently associated with increased PAV (β=0.26, P = .01). In CAD patients who had already been treated with statins, higher VWF levels were associated with a higher coronary plaque burden, suggesting that a high VWF level may be a marker of the residual cardiovascular risk after statin treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative coronary angiogram of the evaluated vessel for IVUS analysis. The target segment for IVUS analysis included the most-diseased cross-section before PCI, and its length was 10 mm. IVUS = intravascular ultrasound, PCI = percutaneous coronary intervention.
Figure 2
Figure 2
Associations between VWF levels and IVUS parameters. PAV (A), lipid volume (B), fibrosis volume (C), dense fibrosis volume (D), and calcification volume (E). IVUS = intravascular ultrasound, PAV = percent atheroma volume, VWF = von Willebrand factor.

Similar articles

Cited by

References

    1. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res 2007;120(suppl 1):S5–9. - PMC - PubMed
    1. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255–65. - PubMed
    1. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007;115:2119–27. - PubMed
    1. Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One 2013;8:e55175. - PMC - PubMed
    1. Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 2014;28:167–78. - PubMed

MeSH terms

Substances